



## ASX ANNOUNCEMENT

21 September 2022

### Placement of \$1.6m to Support US Expansion

**Respiri Limited (ASX:RSH) ("Respiri" or the "Company")**, an eHealth SaaS Company supporting respiratory health management, is pleased to announce that it has completed a placement of \$1.6m to sophisticated investors with management providing \$100,000 to support the expansion into the US.

Marjan Mikel CEO said, "We have had tremendous support over the years from many loyal shareholders and we thank them for their continued support. As an organisation, we look forward to rewarding their patience with some continued commercial traction in the US as we further engage with numerous Hospital and Healthcare Networks.

"Respiri is at an exciting point in its commercial journey, and we are constantly encouraged by the feedback we are receiving from Key Respiratory Consultants and decision makers in various healthcare institutions, resulting in 2 large Hospitals and Healthcare organisations being contracted to supply wheezo to their patients. We hope to update the market on the progress of further commercial developments with new Healthcare organisations in the near term."

As part of the continued push to achieve the best efficiencies within the organisation, management continues to streamline its expenditure and will be announcing some further initiatives to reduce operational costs as well as reductions in Senior Management Salaries, as the Company works to transition from a medical device developer, to generating sales from its unique Asthma Monitoring solution.

The split of funds invested between management and sophisticated investors is such that both the Chairman and the Managing Director have each committed \$50,000 to the capital raise and the remaining \$1.5m of the capital raise monies have been received from sophisticated investors. The issue of shares to both the Chairman and the Managing Director will be subject to shareholder approval for the purposes of ASX Listing Rule 10.11. The Company will seek shareholder approval to the issue of shares to the Chairman and the Managing Director at its annual general meeting.

Shares will be issued to investors pursuant to ASX Listing Rule 7.1A.

**- ENDS -**

**For further information, investors and media please contact:**

**Mr Marjan Mikel**  
CEO & Managing Director  
Respiri Limited  
P: +61 408 462 873  
E: [marjan@respiri.co](mailto:marjan@respiri.co)

**Mr Nicholas Smedley**  
Executive Chairman  
Respiri Limited  
P: +61 447 074 160  
E: [nicholas@respiri.co](mailto:nicholas@respiri.co)

™ wheezo is a trademark of Respiri Limited.

***This ASX announcement has been authorised for release by the Board of Directors of Respiri Limited.***

## About Respi Limited

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo, Respi's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians, and other health care professionals.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

For additional information about Respi and its products, please visit [www.respi.co](http://www.respi.co)

## About wheezo

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

For further information about wheezo, follow the online link <https://wheezo.com>

## Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respi only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.